Finerenone

Public-database records for Finerenone (CAS 1050477-31-0), reproduced here for independent cross-checking.

Safety classification and hazard statements

Reported physical properties

How this substance is indexed

Documented uses

• Finerenone is a selective, nonsteroidal mineralocorticoid receptor antagonist that is used in the therapy of chronic renal disease in patients with type 2 diabetes to slow progression of renal dysfunction and reduce the risk of cardiovascular disease morbidity and mortality. Finerenone has not been linked to serum enzyme elevations during therapy or with instances of clinically apparent liver injury.
• Breast Feeding; Lactation; Mineralocorticoid Receptor Antagonists
• Avoid grapefruit products. Grapefruit products may increase exposure to finerenone, increasing the risk and severity of adverse effects.
• Take with or without food. Food does not have a clinically significant effect on area under the curve.
• Established Pharmacologic Class [EPC] - Nonsteroidal Mineralocorticoid-Receptor Antagonist
• Mechanisms of Action [MoA] - Mineralocorticoid Receptor Antagonists

Names this substance appears under

Finerenone; 1050477-31-0; Kerendia; (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide; BAY94-8862; BAY 94-8862; finerenona; finerenonum; DE2O63YV8R; BAY-94-8862; (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide; DTXSID10146928; RefChem:57201; DTXCID5069419; 814-499-5; Finerenone (BAY 94-8862)

Computed molecular descriptors

Database abstract

Finerenone · CAS 1050477-31-0 · C21H22N4O3. UNII DE2O63YV8R. LogP: 2.51.

Source: PubChem / Wikidata; the batch COA governs where values differ.